OTS

GP Strategies Joins Forces with Quantum5 to Transform Automotive Retail Industry Support

Retrieved on: 
Wednesday, January 3, 2024
Original equipment manufacturer, Workforce, Entrepreneurship, Q5, Partnership, Curriculum, Learning, Human, OTS, ROI, GP, Satellite navigation device

COLUMBIA, Md., Jan. 3, 2024 /PRNewswire/ -- GP Strategies (GP) and Quantum5 (Q5) are joining forces to bring workforce insights and leading-edge learning solutions to OEMs and automotive retail networks in service of the modern learner and a frictionless retail experience.

Key Points: 
  • COLUMBIA, Md., Jan. 3, 2024 /PRNewswire/ -- GP Strategies (GP) and Quantum5 (Q5) are joining forces to bring workforce insights and leading-edge learning solutions to OEMs and automotive retail networks in service of the modern learner and a frictionless retail experience.
  • Automotive retail is changing rapidly, and so are learning and the learner.
  • "We think of ourselves as the Tesla of the learning industry," said Ken Herfurth, Co-Founder and Chief Vision Officer for Q5.
  • We are excited to partner with GP Strategies and to have the opportunity to level up the learning experience across automotive and other industries."

“Don’t Be the ‘I’ in DUI” Media Campaign Encourages Californians to Take Personal Responsibility in Celebrating the Holidays Safely

Retrieved on: 
Monday, December 18, 2023
Other Transport, Automotive, General Automotive, Transport, Law Enforcement, Emergency Services, Public Policy, Government, Transportation, State, Local, Public Safety, Travel, PSAS, Firefighter, Family, Risk, Death, Fresno Police Department, Road traffic safety, Drinking, Friends, Holiday, City, News, OTS, California Department, CHP, Christmas, Radio, Safety, Crash, Ridesharing

The campaign focuses on how nobody wants to be the one who must explain why they drove impaired, got a DUI, and now live with the consequences.

Key Points: 
  • The campaign focuses on how nobody wants to be the one who must explain why they drove impaired, got a DUI, and now live with the consequences.
  • “Those who choose to drink and drive not only senselessly endanger themselves, but everyone else on the roadway.
  • With the holidays approaching, the CHP is intensifying enforcement efforts to quickly remove impaired drivers from our roads,” CHP Commissioner Sean Duryee said.
  • “As you celebrate and enjoy the holidays and festivities, I urge everyone to celebrate safely and never drive under the influence.

Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates

Retrieved on: 
Thursday, November 9, 2023
APOLLO, Sale, Antigen, D, Therapy, ODD, IND, Clinical trial, HMA, EMA, OTS, Patient, Research, U.S. FDA, FDA, SBIR, Committee, HLA, Trial of the century, Bone marrow, Drug discovery, AML, PET-CT, Orphan, Lymphoma, Pharmaceutical industry, Medical imaging

HOUSTON, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today reported corporate updates and financial results for the third quarter ended September 30, 2023.

Key Points: 
  • “During the third quarter of 2023, we continued to diligently advance and execute our clinical objectives across our novel multiTAA-specific T cell pipeline,” commented Juan F. Vera, M.D., President and Chief Executive Officer of Marker Therapeutics.
  • Third Quarter 2023 Financial Highlights:
    Cash Position: Cash and cash equivalents of $17.5 million at September 30, 2023.
  • R&D Expenses: Research and development expenses were $2.0 million for the quarter ended September 30, 2023, compared to $3.6 million for the quarter ended September 30, 2022.
  • G&A Expenses: General and administrative expenses were $1.4 million for the quarter ended September 30, 2023, compared to $3.2 million for the quarter ended September 30, 2022.

Slow Down, Move Over, And Save Lives – Statewide Call to Action During Crash Responder Safety Week

Retrieved on: 
Monday, November 13, 2023
Other Transport, Construction & Property, Automotive, Urban Planning, Transport, Law Enforcement, Emergency Services, Public Policy, Government, Other Automotive, Other Construction & Property, Public Safety, Attention, Television, Road traffic safety, Safety, EMS, Sacramento Metropolitan Fire District, Radio, Firefighter, CCTA, OTS, Death, CHP, Crash, Fatality, Friends, NHTSA, California Highway Patrol, National highway, Family, Move Over, Law enforcement, Motion, Injury, Environment, Name, Norway-America Association, Road, California Department of Transportation

California’s Move Over law requires drivers to move over a lane down when approaching stopped emergency or maintenance vehicles with flashing amber lights.

Key Points: 
  • California’s Move Over law requires drivers to move over a lane down when approaching stopped emergency or maintenance vehicles with flashing amber lights.
  • Caltrans has partnered with the OTS and CHP to launch the “Move Over” campaign.
  • Traffic-related incidents are the leading cause of death for on-duty law enforcement officers, fire, EMS, maintenance workers, and tow/recovery professionals.
  • In 2021, more than 10,000 work-zone crashes occurred on California roadways, resulting in more than 4,500 injuries and 120 fatalities.

Ractigen Presents Preclinical Results of Its saRNA Therapeutic Targeting DMD/BMD at the Oligonucleotide Therapeutics Society (OTS) Annual Meeting

Retrieved on: 
Thursday, November 2, 2023
OTS, SOD1, UTRN, Heart, RNA, BMD, Myopathy, CNS, RNAa, SaRNA, Mouse, MDX, ALS, Duchenne muscular dystrophy, Lead, SCAD, Gene, DMD, Oligonucleotide, Therapy, Patient, Small RNA, Mutation, Vaccine

JIANGSU, China, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Ractigen Therapeutics, a clinical stage biopharmaceutical company founded by the pioneers in RNA activation (RNAa), presented recent preclinical results at the annual meeting of the Oligonucleotide Therapeutics Society (OTS) in Barcelona, Spain.

Key Points: 
  • JIANGSU, China, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Ractigen Therapeutics, a clinical stage biopharmaceutical company founded by the pioneers in RNA activation (RNAa), presented recent preclinical results at the annual meeting of the Oligonucleotide Therapeutics Society (OTS) in Barcelona, Spain.
  • RNAa uses short duplex RNA known as saRNA to target and ‘turn up’ transcription of endogenous genes leading to restoration of their protein function.
  • "We are very excited about the preclinical results of our utrophin activating saRNA and believe that our approach could represent an ideal therapeutic strategy that benefits all DMD and BMD patients," said Long-Cheng Li, CEO of Ractigen Therapeutics.
  • The SCADTM platform has propelled Ractigen’s leading RNA program to the clinic for the treatment of ALS patients with SOD1 mutation.

EQS-News: Secarna Pharmaceuticals presents data at OTS showcasing unique characteristics and factors with a role in the activity and side effect profile of LNA-modified ASOs

Retrieved on: 
Thursday, October 26, 2023
Knowledge, OTS, ASO, LNA, Asos, Doctor of Philosophy, IDO1, Oligonucleotide, TLR9, Kinetics, Patient, Infection, Fine chemical

The two posters were presented this week, at the 19th Annual Meeting of the Oligonucleotide Therapeutics Society (OTS) in Barcelona, Spain.

Key Points: 
  • The two posters were presented this week, at the 19th Annual Meeting of the Oligonucleotide Therapeutics Society (OTS) in Barcelona, Spain.
  • The poster 201: Characterization of immunostimulatory potential of LNA-modified antisense oligonucleotides was presented by Irene Riera Tur, PhD.
  • It could be shown that, among others, LNA-modified ASOs actually can induce activation of the human TLR9 pathway and downstream signaling.
  • “These data confirm our previous studies and convince us that we are on the right path to fully exploit the potential of ASOs.

More than 35 Iconic Canadian Buildings and Landmarks to be Illuminated for World Occupational Therapy Day

Retrieved on: 
Tuesday, October 24, 2023
Person-centered therapy, Confederation Building, CN Tower, Health, Confederation Building (Newfoundland and Labrador), High Level, House of Assembly, Peace Bridge, IG Field, Tower, BC Place, Reconciliation Bridge, OTA, World government, Assembly, Partnership, Community, OTS, Occupational therapy, Employment, High Level Bridge, WFOT, Province House, Nursing, Quinte West, Queen Elizabeth II Court (Regina, Saskatchewan)

Ottawa, Ontario, Oct. 24, 2023 (GLOBE NEWSWIRE) -- On October 27, 2023, more than 35 iconic buildings and landmarks across Canada will light up blue in a show of support for World Occupational Therapy Day, an international day of awareness to acknowledge the work done by occupational therapists (OTs) and occupational therapist assistants (OTAs).

Key Points: 
  • Ottawa, Ontario, Oct. 24, 2023 (GLOBE NEWSWIRE) -- On October 27, 2023, more than 35 iconic buildings and landmarks across Canada will light up blue in a show of support for World Occupational Therapy Day, an international day of awareness to acknowledge the work done by occupational therapists (OTs) and occupational therapist assistants (OTAs).
  • World Occupational Therapy Day promotes and celebrates the profession locally, nationally, and internationally, and the meaningful differences that OTs and OTAs make in the lives of their clients.
  • First launched in 2010 by the World Federation of Occupational Therapists (WFOT), World Occupational Therapy Day has become an important date as it falls in October, which is celebrated as Occupational Therapy Month in Canada.
  • "We are honoured to have the hard work and dedication of the 20,000 OTs and OTAs across Canada recognized by so many iconic landmarks," says Phillip Wendt, President of the Canadian Association of Occupational Therapists.

MiNA Therapeutics Highlights Preclinical Research on RNA Activation (RNAa) Therapeutics Presented at the Oligonucleotide Therapeutics Society (OTS) Annual Meeting

Retrieved on: 
Wednesday, October 25, 2023
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Clinical Trials, Mina, OTS, Acute myeloid leukemia, Therapy, RNA, Bone marrow, Cell, RNAa, Inherit, Gene, Oligonucleotide, AML, Regulation, Vaccine

MiNA Therapeutics Limited, the pioneer in small activating RNA (RNAa) therapeutics, highlights preclinical research presented by academic partners at the annual meeting of the Oligonucleotide Therapeutics Society (OTS) in Barcelona, Spain.

Key Points: 
  • MiNA Therapeutics Limited, the pioneer in small activating RNA (RNAa) therapeutics, highlights preclinical research presented by academic partners at the annual meeting of the Oligonucleotide Therapeutics Society (OTS) in Barcelona, Spain.
  • RNAa therapeutics are a revolutionary new class of medicines that can restore or boost normal function of genes and thereby protein-modulated pathways in cells.
  • Another study titled, “Small-Activating RNA Therapy Development for the Inherited genetic Disorder Aniridia,” revealed the potential of RNAa therapeutics to treat a rare and severe genetic eye disease.
  • “The findings from these three preclinical studies demonstrate continued advances in the development of our novel RNAa therapeutics across a range of therapeutic areas,” said Robert Habib, CEO of MiNA Therapeutics.

ARTHEx Biotech Announces Presentations at the 19th Annual Meeting of the Oligonucleotide Therapeutics Society (OTS) and Tides Europe 2023

Retrieved on: 
Tuesday, October 24, 2023
Poster, Oligonucleotide, OTS, MicroRNA, NL, II, Pharmaceutical industry

VALENCIA, Spain, Oct. 24, 2023 /PRNewswire/ -- ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of microRNAs, announced today the presentation of posters and oral talks at the 19th Annual Meeting of the Oligonucleotide Therapeutics Society (OTS), taking place October 22-25, 2023, in Barcelona, Spain, and Tides Europe 2023, taking place October 30-November 1, 2023, in Amsterdam, NL.

Key Points: 
  • VALENCIA, Spain, Oct. 24, 2023 /PRNewswire/ -- ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of microRNAs, announced today the presentation of posters and oral talks at the 19th Annual Meeting of the Oligonucleotide Therapeutics Society (OTS), taking place October 22-25, 2023, in Barcelona, Spain, and Tides Europe 2023, taking place October 30-November 1, 2023, in Amsterdam, NL.
  • Details of the ARTHEx presentations during OTS are below:
    ARTHEx's posters will be available for viewing during the Poster Sessions I and II, being held on October 24 and October 25, 2023.
  • Titles are listed below:
    "Comprehensive assessment of potential hybridization-dependent off-target effects of ATX-01 including In Silico, In Vitro and In Vivo evaluation."
  • Details of the ARTHEx presentation during Tides Europe is below:
    More information about the Tides Europe meeting can be found here: link .

ARTHEx Biotech Announces Sponsorship and Participation in the Spanish Meeting on Oligonucleotide Therapeutics (SMOT III)

Retrieved on: 
Tuesday, October 24, 2023
Pharmacy, OTS, Faculty, CSO, Generalitat Valenciana, Pennington Biomedical Research Center, Collaboration, Sindicato de Médicos de Asistencia Pública v Conselleria de Sanidad y Consumo de la Generalidad Valenciana, Institute for Small and Medium Industry of the Generalitat Valenciana, SMOT, University, Oligonucleotide, MicroRNA, Pharmaceutical industry

SMOT III is supported by the Conselleria D'Innovació, Universitats, Ciencies i Societat Digital of the Generalitat Valenciana, the Oligonucleotide Therapeutics Society (OTS), and its sponsoring companies, including ARTHEx.

Key Points: 
  • SMOT III is supported by the Conselleria D'Innovació, Universitats, Ciencies i Societat Digital of the Generalitat Valenciana, the Oligonucleotide Therapeutics Society (OTS), and its sponsoring companies, including ARTHEx.
  • ARTHEx and the biomedical research center of Hospital La Fe (IIS La Fe), are organizing the event.
  • In addition, ARTHEx's CSO and co-founder, Beatriz Llamusi, is one of the welcome/closing speakers to the event and will be Chairwoman of certain meeting sessions.
  • Details of the ARTHEx presentations during SMOT III are below:
    More information about SMOT III, including registration details and the program, is located here: link .